glioblastoma

  •   George Lundberg, MD

    This scientific report from Neuro-Oncology outlines findings from a large, randomized clinical trial showing that the drug veliparib (a kind of drug known as a PARP inhibitor) added to radiotherapy and temozolomide did not improve progression-free survival in unmethylated glioblastoma.

    .

  •  

    When is the Best Time to Seek a Clinical Trial for Glioblastoma?

    With: Eric Wong, MD

    For some people with glioblastoma brain tumors, enrolling in a clinical trial enables access to cutting-edge treatment. Here, our Curious Dr. George talks clinical trials with Cancer Commons Expert Physician Advisor, Eric T. Wong, MD. Dr. Wong is also Associate Professor of Neurology at Harvard Medical School and Co-Director of the Brain Tumor Center at Beth Israel Deaconess Medical Center. Curious Dr. George: Malignant… Read more »

  •   George Lundberg, MD

    A press release from ScienceDaily outlines results from a small study of patients receiving a standard, FDA-approved treatment (temozolomide) for glioblastoma. The results suggest that some patients may survive a few months longer, all because of time of day for administering the drug.

    .

  •  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What would you do if… Read more »

  •   George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The extent of tumor resection—how much of the tumor is able to be removed—at the initial surgery is probably the most important factor in prognosis of glioblastoma. This academic research paper explores methods that help surgeons maximize tumor removal.

    Go to full paper published in the Journal of Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from WKYC Studios curated by Editor in Chief George Lundberg, MD, who notes: 

    An experimental treatment in which the virus that causes polio is directly injected into glioblastoma (GBM) tissue has shown some promise, as reported in the New England Journal of Medicine in 2018. This news story from WKYC provides a partial update from an ongoing subsequent clinical trial.

    Go to full article published by WKYC Studios.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    These clinical trial results suggest that six cycles of temozolomide is as effective as 12 for patients with glioblastoma and produces fewer side effects.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.